Displaying items tagged: Tetra Therapeutics

GRAND RAPIDS — Michigan Capital Network plans to form a fourth venture capital fund.

EAST GRAND RAPIDS —Mark Gurney retired as CEO of drug developer Tetra Therapeutics Inc. at the end of June, more than a year after selling the company to Japan-based pharmaceutical company Shionogi & Co. Ltd.

After years of raising millions in capital and federal grant funding for Tetra Therapeutics Inc. — which was developing a new drug that could potentially treat Alzheimer’s disease and a form of autism — Mark Gurney in 2020 finally found the big money he needed to get to the end.

GRAND RAPIDS — Tetra Therapeutics Inc.’s sale to a Japanese pharmaceutical company provides a final pathway toward bringing to market potential new drugs to treat Alzheimer’s disease and a form of autism, as well as generates a handsome return for financial backers.

GRAND RAPIDS — Drug developer Tetra Therapeutics Inc. has reached a definitive merger agreement with Japan-based pharmaceutical company Shionogi & Co. Ltd. in a deal that could reach $500 million.

MiBiz Growth Report for March 15, 2020.

GRAND RAPIDS — Drug developer Tetra Therapeutics has secured a new equity investment from Japanese pharmaceutical company Shionogi & Co. Ltd.

Growth report for Sept. 28, 2019.

GRAND RAPIDS — Tetra Therapeutics says it is enrolling patients faster than expected for a clinical trial on a potential new drug to treat Alzheimer’s disease.